Beren wins FDA approval for long-studied rare disease drug
A molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Therapeutics, developer of Lembaz (adrabetadex) ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.